Hookipa Pharma Inc.

Hookipa Pharma Inc. company information, Employees & Contact Information

At HOOKIPA, we envision a world in which cancers and infectious diseases can be chronically managed or eradicated. HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company advancing the field of immunotherapy through the development of new immunotherapies based on our proprietary arenavirus platform, which is designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. Our pipeline includes wholly owned investigational arenaviral immunotherapies targeting HPV16+ cancers, prostate cancer, KRAS-mutated cancers (including colorectal, pancreatic and lung), and other undisclosed programs. In addition, HOOKIPA aims to develop functional cures for HBV and HIV in collaboration with Gilead. As a company, we fight for innovation; we challenge ourselves to act authentically and transparently; we thrive on our differences; and we go for it, never giving up in our efforts to eliminate the suffering of people with cancer and infectious disease. To learn more please visit www.hookipapharma.com.

Company Details

Employees
52
Founded
-
Address
The Empire State Building, 350 Fifth Avenue,room/suite 7240,austria
Phone
+43 1 890 63 60
Email
of****@****ech.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
New York, New York
Looking for a particular Hookipa Pharma Inc. employee's phone or email?

Hookipa Pharma Inc. Questions

News

HOOKIPA Pharma Announces Intention to Voluntarily Delist and Deregister its Common Stock - Yahoo Finance

HOOKIPA Pharma Announces Intention to Voluntarily Delist and Deregister its Common Stock Yahoo Finance

HOOKIPA Pharma Announces Enrollment Completion of Phase 1b - GlobeNewswire

HOOKIPA Pharma Announces Enrollment Completion of Phase 1b GlobeNewswire

HOOKIPA Pharma Announces Notice to Shareholders Regarding U.K. Disclosure Requirements - Yahoo Finance

HOOKIPA Pharma Announces Notice to Shareholders Regarding U.K. Disclosure Requirements Yahoo Finance

Poolbeg Pharma plc (“Poolbeg” or the “Company”) Combination of Poolbeg and HOOKIPA Pharma Inc. - GlobeNewswire

Poolbeg Pharma plc (“Poolbeg” or the “Company”) Combination of Poolbeg and HOOKIPA Pharma Inc. GlobeNewswire

HOOKIPA Pharma announces FDA clearance of its IND application for HB-500 for the treatment of HIV - European AIDS Treatment Group

HOOKIPA Pharma announces FDA clearance of its IND application for HB-500 for the treatment of HIV European AIDS Treatment Group

HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer - citybiz

HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer citybiz

Game-Changing HIV Vaccine Trial Fully Enrolled: HOOKIPA's Path to Potential Cure - Stock Titan

Game-Changing HIV Vaccine Trial Fully Enrolled: HOOKIPA's Path to Potential Cure Stock Titan

HOOKIPA Pharma announces publication of preclinical data of HBV therapeutic vaccine developed in collaboration with Gilead Sciences - European AIDS Treatment Group

HOOKIPA Pharma announces publication of preclinical data of HBV therapeutic vaccine developed in collaboration with Gilead Sciences European AIDS Treatment Group

HOOKIPA Pharma Appoints Dr. Malte Peters as CEO - citybiz

HOOKIPA Pharma Appoints Dr. Malte Peters as CEO citybiz

HOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead Sciences - citybiz

HOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead Sciences citybiz

HOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead Sciences - GlobeNewswire

HOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead Sciences GlobeNewswire

HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200 - Yahoo Finance

HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200 Yahoo Finance

HOOKIPA Pharma Appoints Terry Coelho to its Board of Directors - citybiz

HOOKIPA Pharma Appoints Terry Coelho to its Board of Directors citybiz

HOOKIPA Pharma to Host Investor Call on HB-200 Data Presented at American Society of Clinical Oncology 2024 Annual Meeting - Yahoo Finance

HOOKIPA Pharma to Host Investor Call on HB-200 Data Presented at American Society of Clinical Oncology 2024 Annual Meeting Yahoo Finance

HOOKIPA Pharma Appoints Katia Schlienger, M.D., Ph.D., Chief Medical Officer and Malte Peters, M.D., to Board of Directors - citybiz

HOOKIPA Pharma Appoints Katia Schlienger, M.D., Ph.D., Chief Medical Officer and Malte Peters, M.D., to Board of Directors citybiz

HOOKIPA Pharma Achieves $5 Million Milestone Payment from Gilead Sciences for Progress in the Development of Hepatitis B Vaccine - Yahoo Finance

HOOKIPA Pharma Achieves $5 Million Milestone Payment from Gilead Sciences for Progress in the Development of Hepatitis B Vaccine Yahoo Finance

Hookipa Pharma announces workforce reduction of 80%, pause of eseba-vec program - Yahoo Finance

Hookipa Pharma announces workforce reduction of 80%, pause of eseba-vec program Yahoo Finance

HOOKIPA Pharma Announces Pricing of Initial Public Offering - GlobeNewswire

HOOKIPA Pharma Announces Pricing of Initial Public Offering GlobeNewswire

Top Hookipa Pharma Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant